星空体育官方入口网站网址大全-登录入口官网

#补体抑制剂#

9篇内容 | 847人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1650583, encodeId=084a165058315, content=<a href='/topic/show?id=64ae90120b4' target=_blank style='color:#2F92EE;'>#补体抑制剂#</a>, objectTitle=长效C5补体抑制剂Ultomiris治疗视神经脊髓炎的III期试验取得积极结果, objectType=article, longId=726365, objectId=c0f8e2636523, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c0f8e2636523, replyNumber=0, likeNumber=71, createdTime=2023-03-13, rootId=0, userName=yahu, userId=c6df24038723, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c0f8e2636523, moduleTitle=长效C5补体抑制剂Ultomiris治疗视神经脊髓炎的III期试验取得积极结果, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=c0f8e2636523)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650582, encodeId=d0ac1650582d3, content=<a href='/topic/show?id=64ae90120b4' target=_blank style='color:#2F92EE;'>#补体抑制剂#</a>, objectTitle=【Nature子刊】新冠死亡率激增！免疫补体和凝血脱不了干系！补体抑制剂亟需开发！, objectType=article, longId=198774, objectId=218e198e7496, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=218e198e7496, replyNumber=0, likeNumber=55, createdTime=2020-09-16, rootId=0, userName=yahu, userId=c6df24038723, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=218e198e7496, moduleTitle=【Nature子刊】新冠死亡率激增！免疫补体和凝血脱不了干系！补体抑制剂亟需开发！, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=218e198e7496)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650581, encodeId=f4b016505814e, content=<a href='/topic/show?id=64ae90120b4' target=_blank style='color:#2F92EE;'>#补体抑制剂#</a>, objectTitle=每周一次皮下注射C5补体抑制剂ULTOMIRIS，治疗阵发性睡眠性血红蛋白尿达到了III期临床终点, objectType=article, longId=196488, objectId=a16319648829, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a16319648829, replyNumber=0, likeNumber=69, createdTime=2021-04-09, rootId=0, userName=yahu, userId=c6df24038723, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a16319648829, moduleTitle=每周一次皮下注射C5补体抑制剂ULTOMIRIS，治疗阵发性睡眠性血红蛋白尿达到了III期临床终点, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=a16319648829)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650576, encodeId=c46716505e695, content=<a href='/topic/show?id=64ae90120b4' target=_blank style='color:#2F92EE;'>#补体抑制剂#</a>, objectTitle=Akari的补体抑制剂Nomacopan治疗小儿造血干细胞移植相关血栓性微血管病，获得FDA快速通道指定, objectType=article, longId=177725, objectId=7f3b1e772586, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7f3b1e772586, replyNumber=0, likeNumber=46, createdTime=2019-12-24, rootId=0, userName=yahu, userId=c6df24038723, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7f3b1e772586, moduleTitle=Akari的补体抑制剂Nomacopan治疗小儿造血干细胞移植相关血栓性微血管病，获得FDA快速通道指定, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=7f3b1e772586)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650580, encodeId=c5c91650580c9, content=<a href='/topic/show?id=64ae90120b4' target=_blank style='color:#2F92EE;'>#补体抑制剂#</a>, objectTitle=EHA 2020：III期头对头研究证实C3补体抑制剂pegcetacoplan治疗阵发性夜间血红蛋白尿疗效显著, objectType=article, longId=195820, objectId=4ad419582055, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4ad419582055, replyNumber=0, likeNumber=62, createdTime=2020-12-05, rootId=0, userName=yahu, userId=c6df24038723, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4ad419582055, moduleTitle=EHA 2020：III期头对头研究证实C3补体抑制剂pegcetacoplan治疗阵发性夜间血红蛋白尿疗效显著, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=4ad419582055)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650577, encodeId=7adf16505e779, content=<a href='/topic/show?id=64ae90120b4' target=_blank style='color:#2F92EE;'>#补体抑制剂#</a>, objectTitle=Akari的补体抑制剂nomacopan治疗造血干细胞移植相关血栓性微血管病变，获得FDA的孤儿药指定, objectType=article, longId=178530, objectId=2cdd1e853070, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2cdd1e853070, replyNumber=0, likeNumber=75, createdTime=2020-05-23, rootId=0, userName=yahu, userId=c6df24038723, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2cdd1e853070, moduleTitle=Akari的补体抑制剂nomacopan治疗造血干细胞移植相关血栓性微血管病变，获得FDA的孤儿药指定, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=2cdd1e853070)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650578, encodeId=a1a616505e8b7, content=<a href='/topic/show?id=64ae90120b4' target=_blank style='color:#2F92EE;'>#补体抑制剂#</a>, objectTitle=Apellis的C3补体抑制剂Pegcetacoplan用于阵发性夜间血红蛋白尿的III期临床成功, objectType=article, longId=185945, objectId=1f6e1859452d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1f6e1859452d, replyNumber=0, likeNumber=62, createdTime=2020-12-22, rootId=0, userName=yahu, userId=c6df24038723, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1f6e1859452d, moduleTitle=Apellis的C3补体抑制剂Pegcetacoplan用于阵发性夜间血红蛋白尿的III期临床成功, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=1f6e1859452d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650579, encodeId=308d16505e93a, content=<a href='/topic/show?id=64ae90120b4' target=_blank style='color:#2F92EE;'>#补体抑制剂#</a>, objectTitle=Blood：C5补体抑制剂Crovalimab治疗阵发性夜间血红蛋白尿, objectType=article, longId=187106, objectId=2d1e18e106e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2d1e18e106e1, replyNumber=0, likeNumber=58, createdTime=2020-02-28, rootId=0, userName=yahu, userId=c6df24038723, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2d1e18e106e1, moduleTitle=Blood：C5补体抑制剂Crovalimab治疗阵发性夜间血红蛋白尿, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=2d1e18e106e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650575, encodeId=0d0a16505e5c6, content=<a href='/topic/show?id=64ae90120b4' target=_blank style='color:#2F92EE;'>#补体抑制剂#</a>, objectTitle=欧盟批准C5补体抑制剂ULTOMIRIS用于治疗阵发性睡眠性血红蛋白尿（PNH）成人患者, objectType=article, longId=174812, objectId=e3031e48124f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e3031e48124f, replyNumber=0, likeNumber=56, createdTime=2019-10-03, rootId=0, userName=yahu, userId=c6df24038723, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e3031e48124f, moduleTitle=欧盟批准C5补体抑制剂ULTOMIRIS用于治疗阵发性睡眠性血红蛋白尿（PNH）成人患者, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=e3031e48124f)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

补体抑制剂

2020-05-29

yahu (审核中...)

前往app查看评论内容

#补体抑制剂#

长效C5补体抑制剂Ultomiris治疗视神经脊髓炎的III期试验取得积极结果

2023-03-13

yahu (审核中...)

前往app查看评论内容

#补体抑制剂#

【Nature子刊】新冠死亡率激增！免疫补体和凝血脱不了干系！补体抑制剂亟需开发！

2020-09-16

yahu (审核中...)

前往app查看评论内容

#补体抑制剂#

每周一次皮下注射C5补体抑制剂ULTOMIRIS，治疗阵发性睡眠性血红蛋白尿达到了III期临床终点

2021-04-09

yahu (审核中...)

前往app查看评论内容

#补体抑制剂#

Akari的补体抑制剂Nomacopan治疗小儿造血干细胞移植相关血栓性微血管病，获得FDA快速通道指定

2019-12-24

yahu (审核中...)

前往app查看评论内容

#补体抑制剂#

EHA 2020：III期头对头研究证实C3补体抑制剂pegcetacoplan治疗阵发性夜间血红蛋白尿疗效显著

2020-12-05

yahu (审核中...)

前往app查看评论内容

#补体抑制剂#

Akari的补体抑制剂nomacopan治疗造血干细胞移植相关血栓性微血管病变，获得FDA的孤儿药指定

2020-05-23

yahu (审核中...)

前往app查看评论内容

#补体抑制剂#

Apellis的C3补体抑制剂Pegcetacoplan用于阵发性夜间血红蛋白尿的III期临床成功

2020-12-22

yahu (审核中...)

前往app查看评论内容

#补体抑制剂#

Blood：C5补体抑制剂Crovalimab治疗阵发性夜间血红蛋白尿

2020-02-28

yahu (审核中...)

前往app查看评论内容

#补体抑制剂#

欧盟批准C5补体抑制剂ULTOMIRIS用于治疗阵发性睡眠性血红蛋白尿（PNH）成人患者

2019-10-03

科室
- - 订阅+
  - 更多科室
工具
服务